|
|
Line 8: |
Line 8: |
| | | |
| <main> | | <main> |
− |
| |
| | | |
| <section class="slice slice-lg"> | | <section class="slice slice-lg"> |
Line 16: |
Line 15: |
| <!-- Article body --> | | <!-- Article body --> |
| <article> | | <article> |
− | <h1>FQ reporter assays Notebook</h1> | + | |
− | <hr>
| + | <h1>Notebook Chromosomal rearrangements</h1> |
− | <h6>Sunday,01/07/2018</h6> | + | <h6>Wednesday, 05/09/18</h6> |
− | <p class="lead">This set of experiments are based on our protocol: Fluorophore-Quencher reporter Cas12a assay.</p> | + | <h3><u>PCR amplification of Bcr-Abl junction</u></h3> |
− | <p class="lead">ts aim is to detect a specific dsDNA sequence (the Activator) with the CRSIPR/Cas12a system. If said sequence is found in the sample, Cas12a will unleash single-stranded DNase acivity and thus cleave every ssDNA found in the sample. We're | + | <p class="lead">In the <b>PCR amplification of Bcr-Abl junction</b> series of experiments, we want to amplify the Bcr-Abl junction in order to detect it further with LbCas12a. We're going to start from extremely low concentrations of template (1 pM and/or |
− | using this mechanism to get a fluorescent read out using DNaseAlert (ssDNA reporters).</p>
| + | 10 fM) and try to amplify them with different primers (three forward primers and two reverse primers), each containing an inserted PAM sequence. There are two main aims:</p> |
− | <br>
| + | |
− | <p class="lead">Our template is made of a non target strand (NTS) and a target strand (TS) (target 1_NTS /target 1_TS cf. supplementary materials of <i>Chen, J. S. et al</i>.)</p>
| + | |
| <ul> | | <ul> |
− | <p class="lead">NTS (non targeting strand): G C T T G T G G C C G T T T A C G T C G C C G T C C A G C T C G A C C A G G A T G G G C A C C A C C C C G G C</p> | + | <li>Overcome the fact that there might exist no suitable PAM sequence (TTTN for Cas12a) nearby the SNP site or junction, for the Cas12a recognition assay. </li> |
− | <p class="lead">TS (targeting strand): G C C G G G G T G G T G C C C A T C C T G G T C G A G C T G G A C G G C G A C G T A A A C G G C C A C A A G C</p> | + | <li>Prove that these fragments can be specifically detected in very small quantities by combining the sensitivity of PCR amplification method and the specificity of CRISPR-Cas system, this in order to get as close as possible to the concentrations |
| + | present in the blood, and so be able to establish a proof of concept about the possibility of such detection in blood plasma.</li> |
| + | |
| </ul> | | </ul> |
− | <p class="lead">The TS is the strand which will be recognized by the cas12a and thus is complementary to the crRNA.</p> | + | <p class="lead">Please reffer to the PCR using Phusion® High-Fidelity DNA Polymerase protocol.</p> |
− | <p class="lead">We annealed our NTS and TS strand according to our annealing protocol: this is are activator/target.</p>
| + | |
| <br> | | <br> |
− | <p class="lead">We transcribed our crRNA using our transcription protocol from the following sequence:</p> | + | <p class="lead"><b>Approach:</b> We ordered the sequence corresponding to the junction as gBlocks from Integrated DNA Technology (IDT), as well as several base pairs of the two normal genes (Bcr and Abl) (<b>Fig.2, 3</b>) that extend on both sides of the |
| + | junction. Primer oligos were ordered from IDT (c.f. <b>Fig.1</b>):</p> |
| + | <p class="lead">Forward primers (from top to bottom, <b>Fig.1</b> below):</p> |
| <ul> | | <ul> |
− | <p class="lead">G G T C G A G C T G G A C G G C G A C G A T C T A C A C T T A G T A G A A A T T A C C T A T A G T G A G T C G T A T T A A G</p> | + | <li><b>F_primer_chromo_symu_01 (F1)</b></li> |
| + | <li><b>F_primer_chromo_symu_04 (F4)</b></li> |
| + | <li><b>F_primer_chromo_symu_03 (F3)</b></li> |
| + | </ul> |
| + | <p class="lead">Reverse primers (from left to right, <b>Fig.1</b> below):</p> |
| + | <ul> |
| + | <li><b>R_primer_chromo_symu_02 (R2)</b></li> |
| + | <li><b>R_primer_chromo_symu_01 (R1)</b></li> |
| </ul> | | </ul> |
− |
| |
− |
| |
− | <hr>
| |
− | <h6>Monday 30/07/18</h6>
| |
− | <h3>Testing Cas12a complex + DNaseAlert</h3>
| |
− | <p class="lead">Simple experience to test whether the CRISPR/cas12a system works (i.e. if the crRNA was correctly designed and did form a complex with the cas12a which should eventually cleave the ssDNA reporter (DNaseAlert).</p>
| |
| <br> | | <br> |
− | <p class="lead">To get optimal results we've mixed the protocols found in the Supplementary materials of the paper stated above and the protocol given with the lba cas12a from <a href="https://international.neb.com/protocols/2017/12/19/in-vitro-digestion-of-dna-with-engen- | + | <p class="lead">Resuspension of the gBlocks/Oligos was done as following, according to this protocol: |
− | lba-cas12a-cpf1-neb-m0653">NEB</a></p>
| + | </p> |
| + | <a href="#">Oligonucleotides/gBlocks Resuspension and Storage (IDT)</a> |
| + | <table> |
| + | <tr> |
| + | <th>gBlocks/Oligos</th> |
| + | <th>Amount delivered (nmol)</th> |
| + | <th>Desired concentration</th> |
| + | <th>Amount of water to ass (ul)</th> |
| + | </tr> |
| + | <tr> |
| + | <td>Bcr-Abl template</td> |
| + | <td>0.002077</td> |
| + | <td>100 nM</td> |
| + | <td>20.8</td> |
| + | </tr> |
| + | <tr> |
| + | <td>Abl</td> |
| + | <td>0.002492</td> |
| + | <td>100 nM</td> |
| + | <td>24.9</td> |
| + | </tr> |
| + | <tr> |
| + | <td>Bcr</td> |
| + | <td>0.002060</td> |
| + | <td>100 nM</td> |
| + | <td>20.6</td> |
| + | </tr> |
| + | <tr> |
| + | <td>F_primer_Chromo_symu_01</td> |
| + | <td>75.1</td> |
| + | <td>100 µM</td> |
| + | <td>751</td> |
| + | </tr> |
| + | <tr> |
| + | <td>F_primer_chromo_symu_03</td> |
| + | <td>74.4</td> |
| + | <td>100 µM</td> |
| + | <td>744</td> |
| + | </tr> |
| + | <tr> |
| + | <td>F_primer_chromo_symu_04</td> |
| + | <td>66.6</td> |
| + | <td>100 µM</td> |
| + | <td>666</td> |
| + | </tr> |
| + | <tr> |
| + | <td>R_primer_chromo_symu_02</td> |
| + | <td>73.1</td> |
| + | <td>100 µM</td> |
| + | <td>731</td> |
| + | </tr> |
| + | </table> |
| | | |
− | <h4>Protocol:</h4>
| + | <p class="lead"><b>Template DNA</b> solutions (dilutions) were prepared as below:</p> |
− | <p class="lead"><strong>Final sample (20μl) : Cas12a (50nM), crRNA (62nM), activator (1nM), DNaseAlert (50nM), NEBuffer 10x (1x)</strong></p> | + | <ul> |
− | <ol> | + | <li>Bcr-Abl (<b>BA-</b>)</li> |
− | <li>Add 2μl of nuclease free water</li> | + | <li>Bcr (<b>BC-</b>)</li> |
− | <li>Add 2μl of NEBuffer</li>
| + | <li>Abl (<b>AB-</b>)</li> |
− | <li>Add 1μl of Cas12a (1μM)</li> | + | </ul> |
− | <li>Add 1μl of crRNA (1.37 μM)</li> | + | <table> |
− | <li>Incubate 10 minutes at room temperatures</li> | + | <tr> |
− | <li>Add 4μl of activator (5nM 4.a)</li> | + | <th>Dilution (label)</th> |
− | <li>Incubate 10 minutes at 37°C</li>
| + | <th>Final concentration</th> |
− | <li>Add 10μl of DNaseAlert (single use tube diluted in 40μl)</li> | + | <th>Amount of template to take (ul)</th> |
− | <li>Let incubate in 37°C</li>
| + | <th>Nuclease free water (ul)</th> |
− | <li>Look at the fluorescence at desired times (here we checked the fluorescence after ~10minutes)</li> | + | <th>Dilution fold</th> |
− | </ol> | + | </tr> |
| + | <tr> |
| + | <td>BA-1</td> |
| + | <td>1 nM</td> |
| + | <td>2 (from resuspended 100 µM Bcr-Abl stock)</td> |
| + | <td>198</td> |
| + | <td>1:100 dilution</td> |
| + | </tr> |
| + | <tr> |
| + | <td>BA-2</td> |
| + | <td>10 pM</td> |
| + | <td>2 (from BA-1 dilution 1)</td> |
| + | <td>198</td> |
| + | <td>1:100 dilution</td> |
| + | </tr> |
| + | <tr> |
| + | <td>BA-3</td> |
| + | <td>1 pM</td> |
| + | <td>10 (from BA-2 dilution)</td> |
| + | <td>90</td> |
| + | <td>1:10 dilution</td> |
| + | </tr> |
| + | <tr> |
| + | <td>BA-4</td> |
| + | <td>100 fM</td> |
| + | <td>10 (from BA-3 dilution)</td> |
| + | <td>90</td> |
| + | <td>1:10 dilution</td> |
| + | </tr> |
| + | <tr> |
| + | <td>BA-5</td> |
| + | <td>10 fM</td> |
| + | <td>10 (from BA-4 dilution)</td> |
| + | <td>90</td> |
| + | <td>1:10 dilution</td> |
| + | </tr> |
| + | <tr> |
| + | <td>BA-6</td> |
| + | <td>1 fM</td> |
| + | <td>10 (from BA-5 dilution)</td> |
| + | <td>90</td> |
| + | <td>1:10 dilution</td> |
| + | </tr> |
| + | </table> |
| | | |
− | <p class="lead"><strong>Negative control (done at the same time as the sample)</strong></p> | + | <table> |
− | <ol>
| + | <tr> |
− | <li>Add 3μl of Nuclease free water</li> | + | <th>BC-1</th> |
− | <li>Add 2μl of NEBuffer</li>
| + | <th>1 nM</th> |
− | <li>Add 1μl of crRNA</li>
| + | <th>2 (from resuspended Bcr 100 nM stock)</th> |
− | <li>Incubate for 10 minutes at room temperature (with other sample)</li> | + | <th>198</th> |
− | <li>Add 4 μl of activator</li> | + | <th>1:100</th> |
− | <li>Incubate for 10 minutes at 37°C (with other sample)</li>
| + | </tr> |
− | <li>Add 10μl of DNaseAlert (single use tube diluted in 40μl)</li> | + | <tr> |
− | <li>Look at the fluorescence at desired times (here we checked the fluorescence after ~10minutes)</li> | + | <td>BC-2</td> |
| + | <td>10 pM</td> |
| + | <td>2 (from BC-1 dilution)</td> |
| + | <td>198</td> |
| + | <td>1:100</td> |
| + | </tr> |
| + | <tr> |
| + | <td>BC-3</td> |
| + | <td>1 pM</td> |
| + | <td>10 (from BC-2 dilution)</td> |
| + | <td>90</td> |
| + | <td>1:10</td> |
| + | </tr> |
| + | <tr> |
| + | <td>BC-4</td> |
| + | <td>100 fM</td> |
| + | <td>10 (from BC-3 dilution)</td> |
| + | <td>90</td> |
| + | <td>1:10</td> |
| + | </tr> |
| + | <tr> |
| + | <td>BC-5</td> |
| + | <td>10 fM</td> |
| + | <td>10 (from BC-4 dilution)</td> |
| + | <td>90</td> |
| + | <td>1:10</td> |
| + | </tr> |
| + | <tr> |
| + | <td>BC-6</td> |
| + | <td>1 fM</td> |
| + | <td>10 (from BC-5 dilution)</td> |
| + | <td>90</td> |
| + | <td>1:10</td> |
| + | </tr> |
| + | </table> |
| | | |
| + | <table> |
| + | <tr> |
| + | <th>AB-1</th> |
| + | <th>1 nM</th> |
| + | <th>2 (from resuspended Abl 100 nM stock)</th> |
| + | <th>198</th> |
| + | <th>1:100</th> |
| + | </tr> |
| + | <tr> |
| + | <td>AB-2</td> |
| + | <td>10 pM</td> |
| + | <td>2 (from AB-1)</td> |
| + | <td>198</td> |
| + | <td>1:100</td> |
| + | </tr> |
| + | <tr> |
| + | <td>AB-3</td> |
| + | <td>1 pM</td> |
| + | <td>10 (from AB-2)</td> |
| + | <td>90</td> |
| + | <td>1:10</td> |
| + | </tr> |
| + | <tr> |
| + | <td>AB-4</td> |
| + | <td>100 fM</td> |
| + | <td>10 (from AB-3)</td> |
| + | <td>90</td> |
| + | <td>1:10</td> |
| + | </tr> |
| + | <tr> |
| + | <td>AB-5</td> |
| + | <td>10 fM</td> |
| + | <td>10 (from AB-4)</td> |
| + | <td>90</td> |
| + | <td>1:10</td> |
| + | </tr> |
| + | <tr> |
| + | <td>AB-6</td> |
| + | <td>1 fM</td> |
| + | <td>10 (from AB-5)</td> |
| + | <td>90</td> |
| + | <td>1:10</td> |
| + | </tr> |
| + | </table> |
| + | <p class="lead">Then, the 10 µM dilutions of the primers (for PCR use) were prepared:</p> |
| + | <table> |
| + | <tr> |
| + | <th>Primers (100um stock solution)</th> |
| + | <th>Volume to take (ul)</th> |
| + | <th>Amount of water to add (ul)</th> |
| + | <th>Total volume (ul)</th> |
| + | <th>Tube label</th> |
| + | </tr> |
| + | <tr> |
| + | <td>F_primer_Chromo_symu_01</td> |
| + | <td>10</td> |
| + | <td>90</td> |
| + | <td>100</td> |
| + | <td>F1</td> |
| + | </tr> |
| + | <tr> |
| + | <td>F_primer_chromo_symu_03</td> |
| + | <td>10</td> |
| + | <td>90</td> |
| + | <td>100</td> |
| + | <td>F3</td> |
| + | </tr> |
| + | <tr> |
| + | <td>F_primer_chromo_symu_04</td> |
| + | <td>10</td> |
| + | <td>90</td> |
| + | <td>100</td> |
| + | <td>F4</td> |
| + | </tr> |
| + | <tr> |
| + | <td>R_primer_chromo_symu_01</td> |
| + | <td>10</td> |
| + | <td>90</td> |
| + | <td>100</td> |
| + | <td>R1</td> |
| + | </tr> |
| + | <tr> |
| + | <td>R_primer_chromo_symu_02</td> |
| + | <td>10</td> |
| + | <td>90</td> |
| + | <td>100</td> |
| + | <td>R2</td> |
| + | </tr> |
| + | </table> |
| | | |
− | </ol> | + | <figure class="figure"> |
| + | <img alt="Image" src="https://2018.igem.org/File:T--EPFL--_Overview_of_the_junction_and_primer_sequences..png" class="img-fluid rounded" width="800"> |
| + | <figcaption class="mt-3 text-muted">Figure 1. Overview of the junction and primer sequences.</figcaption> |
| + | </figure> |
| | | |
| + | <figure class="figure"> |
| + | <img alt="Image" src="https://2018.igem.org/File:T--EPFL--_Overview_of_the_junction_and_primer_sequences2.png" class="img-fluid rounded" width="800"> |
| + | <figcaption class="mt-3 text-muted">Figure 2. Bcr sequence ordered. Shown in green is the piece of the gene involved in the chromosomal rearrangement ("bcr gene" annotated fragment in fig.1). Also shown in light brown the annealing position of the forward primer one (F1) |
| + | on this gene.</figcaption> |
| + | </figure> |
| | | |
| + | <figure class="figure"> |
| + | <img alt="Image" src="https://2018.igem.org/File:T--EPFL--_Overview_of_the_junction_and_primer_sequences3.png" class="img-fluid rounded" width="800"> |
| + | <figcaption class="mt-3 text-muted">Figure 3. Abl sequence ordered. Shown in blue the piece of the gene involved in the chromosomal rearrangement ("abl gene" annotated fragment in fig.1). Also shown in light brown and grey the annealing positions of the reverse primer one |
| + | (R1) and two (R2) on this gene, respectively</figcaption> |
| + | </figure> |
| | | |
− | <h4>Results</h4> | + | <h5>Hypothesis:</h5> |
| + | <ul> |
| + | <li>Bcr-Abl DNA sequence amplification should result in an amplicon of 105-109 bp when using R2 primer and either of the forward ones, or 142-146 bp if using R1 primer.</li> |
| + | <li>Amplification of Bcr and Abl fragments is linear (i.e. only forward primer annealing on Bcr template, reverse on Abl) rather than exponential, meaning that we shouldn't be able to observe it on the gel, given the low initial concentration |
| + | (1 pM or 10 fM). Also, amplification of Bcr fragment should result in an amplicon of ~239 bp (F1 primer), while for Abl, the amplicon obtained with R1 is of 316 bp length, and 279 for R2 (see <b>Fig.4</b>):</li> |
| + | </ul> |
| | | |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/7/7e/T--EPFL--DNaseAlert_test.png" class="img-fluid rounded" width="500"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/6/63/T--EPFL--_Overview_of_the_junction_and_primer_sequences4.png" class="img-fluid rounded" width="800"> |
| + | <figcaption class="mt-3 text-muted">Figure 4-a. Overview of the Bcr amplicon with primer F1. </figcaption> |
| + | </figure> |
| | | |
| + | <figure class="figure"> |
| + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/d/d0/T--EPFL--_Overview_of_the_junction_and_primer_sequences5.png" class="img-fluid rounded" width="800"> |
| + | <figcaption class="mt-3 text-muted">Figure 4-b. Overview of the Abl amplicon with respectively primer R1 and R2 (from right to left).</figcaption> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis/Discussion</h4> | + | <h3>Cas12a detection assays</h3> |
− | <p class="lead">As it can be seen on the picture there are some fluorescence from the sample with the activator and none from the negative control (without cas12a). This suggest that our <strong>CRISPR/cas12a system activates correctly the DNaseAlert. BUT</strong> the negative control should have been the same as the other sample without the activator to see if cas12a truly only gains its nuclease activity when the activator is present in the sample.</p> | + | <p class="lead">In this series of experiments, we want to be able to detect specifically the presence of the junction (previously amplified by PCR), using Cas12a system. Recognition of the activator by the crRNA unleashes indiscriminate single-stranded |
| + | DNA (ssDNA) cleavage activity by Cas12a that will completely degrades our ssDNA reporter molecules (DNaseAlert, IDT), which results in a higher fluorescent signal. For the CRISPR RNA design (crRNA), we chose to use a shorter guide sequence |
| + | (17 bp rather than 20), designed to recognize the sequence right after the PAM introduced by primer F1, F3 but not F4. First, the choice of using a shorter crRNA is based on the work done by Li S, Cheng Q, Wang J et al.1, where they proved |
| + | that point mutations within a large region (1st–16th bases) resulted in more than 2-fold difference in fluorescence signals for both 16-nt and 17-nt crRNA guide sequences. </p> |
| | | |
− | <h6>Tuseday 31/07/18</h6> | + | <p class="lead">We followed the <a href="#">Fluorophore-Quencher reporter Cas12a assay</a>. crRNAs oligo fragments were annealed with a T7 primer and transcribed then purified following respectively the <a href="#">crRNA Transcription using T7 RNA Polymerase (Promega)</a> and <a href="#">crRNA purification (ZYMO Research RNA Clean & Concentrator™-5 Kit)</a> protocols.</p> |
− | <h3>Trial 1 (50 nM Cas12a, 62.5 nM crRNA, 50 nM DNaseAlert, NEBuffer 2.1)</h3>
| + | |
| | | |
− | <p class="lead">This experiment contained 50 nM of DNaseAlert and negative control contained only DNaseAlert (in addition to buffer) Incubation step (30min/37°C) at the following concentrations: Lbcas12a 250nM / crRNA 320nM. We made different samples with | + | <br> |
− | different activator concentrations : 1nM-1μM.</p> | + | |
| + | <h5>Hypothesis:</h5> |
| + | <ul> |
| + | <li>Cas12a enzyme should be activated by two of the amplified templates (Bcr and Bcr-Abl junction); however, we should detect a signal that is 2-fold less (at least) intense when using the separate gene (Bcr) as activator, since it's target |
| + | strand (TS, not shown here for clarity) present several mismatches with the used crRNA, which is identical to the non-target strand (NTS) (see <b>Fig.5</b>).</li> |
| + | <li>Also, Abl amplified fragment should not activate the Cas12a system, since it's amplified only with one reverse primer that does not contain the PAM sequence.</li> |
| + | <li>Moreover, fragments amplified with the forward primer four (F4) should not activate the Cas neither, since the PAM sequence is shifted from a base.</li> |
| + | </ul> |
| | | |
− | <h4>Results:</h4>
| |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/5/55/T--EPFL--FQ_reporter_assay_trial1.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/a/a3/T--EPFL--_Overview_of_the_junction_and_primer_sequences6.png" class="img-fluid rounded" width="800"> |
| + | <figcaption class="mt-3 text-muted">Figure 5-a. Alignment of the target region (NTS) in the ordered DNA sequence of Bcr-Abl (top) and the crRNA guide sequence (spacer) used for detection (bottom). The guide sequence is the same as the NTS, there is no mismatches.</figcaption> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis:</h4> | + | <figure class="figure"> |
− | <p class="lead">Controls seem to work and the enzyme seems to be activated, since we can measure fluorescence in all samples. Also, those with higher concentrations of template DNA exhibit more fluorescence, except for the 100 nM sample which has a fluorescence
| + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/6/6d/T--EPFL--_Overview_of_the_junction_and_primer_sequences7.png" class="img-fluid rounded" width="800"> |
− | higher than the 1 μM sample.</p>
| + | <figcaption class="mt-3 text-muted">Figure 5-b. Alignment of the CRISPR-Cas12a target region on the Bcr ordered fragment (NTS, sequence on top) and the crRNA guide sequence (spacer) used for detection (bottom). The guide sequence is not the same as the NTS (4 different base |
| + | pairs), i.e. four mismatches with the corresponding target strand (TS) are expected.</figcaption> |
| + | </figure> |
| | | |
− | <h4>Discussion</h4> | + | <figure class="figure"> |
− | <p class="lead">Overall, controls seem to work, samples with higher concentrations of template DNA exhibit more fluorescence, except for the 100 nM sample which has a fluorescence higher than the 1μM sample. Regarding this, we could have inverted the samples.
| + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/e/ea/T--EPFL--_Overview_of_the_junction_and_primer_sequences8.png" class="img-fluid rounded" width="800"> |
− | Another explanation would be that for higher concentration of activator, the enzyme might be cleaving that instead of DNaseAlert reporter. The negative control should be cas12a with crRNA without any template. We'll modify this for the
| + | <figcaption class="mt-3 text-muted">Figure 5-c. Alignment of the CRISPR-Cas12a target region on the Abl ordered fragment (NTS, sequence on top) and the crRNA guide sequence (spacer) used for detection (bottom). The guide sequence is not the same as the NTS (3 different base |
− | next experiment.</p>
| + | pairs), i.e. three mismatches with the corresponding target strand (TS) are expected.</figcaption> |
| + | </figure> |
| | | |
− | <hr>
| |
| | | |
− | <h6>Thursday 02/08/2018</h6> | + | <h3><u>PCR amplification of Bcr-Abl junction-Trial 1</u></h3> |
| + | <p class="lead">In this version, <b>we're performing the assay with one forward primer only</b> (F_primer_Chromo_symu_01), the second reverse primer (R_primer_chromo_symu_02)<b>and different annealing temperatures for the PCR reactions,</b> i.e. three duplicates |
| + | of the two samples (A-A1), in order to select the right temperature to use for the amplification, since it was difficult to estimate the melting temperature of the primers due to the mismatches with the template sequence.</p> |
| + | <ul> |
| + | <li>59 °C : 1st duplicate. </li> |
| + | <li>64 °C: 2nd duplicate. </li> |
| + | <li>69°C: 3rd duplicate.</li> |
| + | </ul> |
| + | |
| + | <table style="border-collapse:collapse;border-spacing:0" class="tg"> |
| + | <tr> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Amounts (1ul)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">A (1pM)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">A1 (10fM)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">A (10pM)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">A1 (10fM)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">A (1 pM)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">A1 (10 fM)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">(-) PCR control</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Master Mix (7.5 x)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Final concentrations</th> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Nuclease-free water</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#ffcc67;text-align:left;vertical-align:top">213.75</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5X Phusion HF buffer</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#ffcc67;text-align:left;vertical-align:top">75</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1X</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10 mM dNTPs</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#ffcc67;text-align:left;vertical-align:top">7.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">200 µM</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">From Master mix</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#f8a102;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#f8a102;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#f8a102;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#f8a102;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#f8a102;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#f8a102;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#f8a102;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">296.25</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10 µM F1-10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5 µM</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10 µM R2-10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5 µM</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">100 fM Template (BA-4)</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10 fM</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10 pM Template (BA-2)</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1 pM</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Nuclease-free water</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Phusion DNA Polymerase</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1.0 units/50 µl PCR</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Total volume</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | </tr> |
| + | </table> |
| + | |
| + | <p class="lead">The thermocycler was programmed as described below. <b>IMPORTANT</b>: three blocs were used for proceding with the samples simultaneously, since we have three sets with different forward primers.</p> |
| + | <table style="undefined;table-layout: fixed; width: 870px"> |
| + | <colgroup> |
| + | <col style="width: 617px"> |
| + | <col style="width: 183px"> |
| + | <col style="width: 70px"> |
| + | </colgroup> |
| + | <tr> |
| + | <th>Temperature</th> |
| + | <th>Time</th> |
| + | <th></th> |
| + | </tr> |
| + | <tr> |
| + | <td>98 °C</td> |
| + | <td>30 sec (Initial Denaturation)</td> |
| + | <td></td> |
| + | </tr> |
| + | <tr> |
| + | <td>98 °C</td> |
| + | <td>10 sec (denaturation)</td> |
| + | <td>35 cycles</td> |
| + | </tr> |
| + | <tr> |
| + | <td>59 °C : 1st duplicate. 64 °C: 2nd duplicate. 69°C: |
| + | 3rd duplicate</td> |
| + | <td>30 sec (primer annealing)</td> |
| + | <td>35 cycles</td> |
| + | </tr> |
| + | <tr> |
| + | <td>72 °C</td> |
| + | <td>30 sec (extension)</td> |
| + | <td>35 cycles</td> |
| + | </tr> |
| + | <tr> |
| + | <td>72 °C</td> |
| + | <td>10 min (Final Extension)</td> |
| + | <td></td> |
| + | </tr> |
| + | <tr> |
| + | <td>4 °C</td> |
| + | <td></td> |
| + | <td></td> |
| + | </tr> |
| + | </table> |
| + | |
| + | <p class="lead"></p> |
| + | <p class="lead">As controls, we prepared a PCR negative control sample in which we only add water and no template (D), and two others (N and N1) that contain the initial concentrations of template without amplification (in order to be sure that we can't |
| + | detect these without amplification). Gel was load as following:</p> |
| + | |
| + | <table> |
| + | <tr> |
| + | <th>Lane</th> |
| + | <th>1</th> |
| + | <th>2</th> |
| + | <th>3</th> |
| + | <th>4</th> |
| + | <th>5</th> |
| + | <th>6</th> |
| + | <th>7</th> |
| + | <th>8</th> |
| + | </tr> |
| + | <tr> |
| + | <td>Sample</td> |
| + | <td>Generuler 1kb Plus DNA Ladder</td> |
| + | <td>A (59°C)</td> |
| + | <td>A1 (59°C)</td> |
| + | <td>A (64°C)</td> |
| + | <td>A1 (64°C)</td> |
| + | <td>A (69°C)</td> |
| + | <td>A1 (69°C)</td> |
| + | <td>D</td> |
| + | </tr> |
| + | <tr> |
| + | <td>µl</td> |
| + | <td>5</td> |
| + | <td>12</td> |
| + | <td>12</td> |
| + | <td>12</td> |
| + | <td>12</td> |
| + | <td>12</td> |
| + | <td>12</td> |
| + | <td>12</td> |
| + | </tr> |
| + | </table> |
| | | |
− | <h3>Trial 2 (50 nM Cas12a, 62.5 nM crRNA, 100 nM DNaseAlert, NEBuffer)</h3> | + | <h4 class="text-muted">Results</h4> |
− | <p class="lead">We did this experiment using Nebuffer 2.1 protocol and added a negative control sample containing this time Cas12a enzyme. Incubation step (30min/37°C) at the following concentrations: Lbcas12a 250nM / crRNA 320nM. We made different samples
| + | |
− | with different activator concentrations : 1nM-1μM.</p>
| + | |
| | | |
− | <h4>Results:</h4>
| |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/c/c0/T--EPFL--FAQ_reporter_assay2.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/8/81/T--EPFL--PCR_amplification_of_Bcr-Abl_junction-Trial_1.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis:</h4> | + | <h4 class="text-muted">Analysis/Discussion</h4> |
− | <p class="lead">We can see the increase in the level of fluorescence signal (again 1 μM is below 100 nM activator in terms of fluorescence). Moreover, the negative control level is mostly above the ones with activators.</p> | + | <p class="lead">Overall, <b>an amplification was obtained for all annealing temperatures tested</b>, and we were able to detect the <b>expected amplicon of 105 bp</b>. Moreover, we couldn't observe any band in the negative control's lane, which means that |
| + | our samples were free from any DNA contamination. We can however argue that <b>we got a better amplification when the annealing step was performed under 69°C</b>.</p> |
| + | <p class="lead">We can state that the most efficient amplification was achieved when we annealed our primers (forward F1 and reverse R2) at 69°C. Since it was the one found using the Neb calculator (that doesn't take into account mismatches though), we |
| + | decided to trust it for our further amplifications.</p> |
| | | |
− | <h4>Discussion</h4> | + | <h4 class="text-muted">References</h4> |
− | <p class="lead">It seems that Cas12a could be activated even without binding to the activator.. Or maybe we put some DNA by mistake. The pattern of fluorescence as a function of concentration is still not what we would expect (more fluorescence for concentrated | + | <p class="lead">1.Li, S., Cheng, Q., Wang, J., Zhao, G. & Wang, J. CRISPR-Cas12a-assisted nucleic acid detection. 5,1–8</p> |
− | samples). We’re planning on using Binding buffer for next trial.</p>
| + | |
| | | |
| + | <h6>Thursday, 06/09/18</h6> |
| + | <h3><u>PCR amplification of Bcr-Abl junction-Trial 2.</u></h3> |
| + | <p class="lead">In this version, we performed the assay with our three different forward primers (TTTN PAM sequence introduced with two mutations near a thymine, different lengths, GC content, annealing temperatures) and R_primer_chromo_symu_02 (R2) reverse |
| + | primer, to see which one works the best (in terms of amplification). The annealing temperatures for each set of primers (one reverse primer used), was calculated using NEB Tm calculator. As controls, we prepared a PCR negative control |
| + | sample in which we only add water and no template, and two others that contain the initial concentrations of template without amplification (in order to be sure that we can't detect these without amplification).</p> |
| + | <p class="lead"><i>Read notes of 05/09 for approach and hypothesis for the general "PCR amplification of Bcr-Abl junction" assay.</i></p> |
| + | <ul> |
| + | <li>PCR samples:</li> |
| + | <table style="border-collapse:collapse;border-spacing:0" class="tg"> |
| + | <tr> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Amounts (ul)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">A (1pM template)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">A1 (10 pM template)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">B (1 pM template)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">B1 (10 fM template)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">C (1 pM template)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">C1 (10 fM template)</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">D: (-) PCR control</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Master Mix</th> |
| + | <th style="font-family:Arial, sans-serif;font-size:14px;font-weight:normal;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Final concentrations</th> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Nuclease-free water</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">28.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#ffcc67;text-align:left;vertical-align:top">270.75</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5X Phusion HF buffer</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#ffcc67;text-align:left;vertical-align:top">95</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1X</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10 mM dNTPs</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#ffcc67;text-align:left;vertical-align:top">9.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">200 µM</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">From Master mix</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#ffcc67;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#ffcc67;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#ffcc67;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#ffcc67;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#ffcc67;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#ffcc67;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;background-color:#ffcc67;text-align:left;vertical-align:top">39.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">375.25</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10 µM F1-10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5 µM</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10 µM F3-10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5 µM</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10 µM F4-10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5 µM</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10 µM R2-10</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">2.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5 µM</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Nuclease-free water</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">100 fM Bcr-Abl Template (BA-4)</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10 fM</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">10 pM Bcr-Abl Template (BA-2)</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1 pM</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Phusion DNA Polymerase</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">0.5</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">1.0 units/50 µl PCR</td> |
| + | </tr> |
| + | <tr> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">Total volume</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">50</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | <td style="font-family:Arial, sans-serif;font-size:14px;padding:10px 5px;border-style:solid;border-width:1px;overflow:hidden;word-break:normal;border-color:black;text-align:left;vertical-align:top">-</td> |
| + | </tr> |
| + | </table> |
| | | |
− | <hr> | + | <li>The thermocycler was programmed as described below. <b>IMPORTANT</b>: three blocs were used for proceding with the samples simultaneously, since we have three sets with different forward primers.</li> |
| + | |
| + | <table> |
| + | <tr> |
| + | <th>98 °C</th> |
| + | <th>30 sec (Initial Denaturation)</th> |
| + | <th></th> |
| + | </tr> |
| + | <tr> |
| + | <td>98 °C</td> |
| + | <td>10 sec (denaturation)</td> |
| + | <td>35 cycles</td> |
| + | </tr> |
| + | <tr> |
| + | <td>A-A1-D (F1/R2): 69°C. B-B1 (F3/R2): 72°C. C-C1 |
| + | (F4/R2): 72°C.</td> |
| + | <td>30 sec (primer annealing)</td> |
| + | <td>35 cycles</td> |
| + | </tr> |
| + | <tr> |
| + | <td>72 °C</td> |
| + | <td>30 sec (extension)</td> |
| + | <td>35 cycles</td> |
| + | </tr> |
| + | <tr> |
| + | <td>72 °C</td> |
| + | <td>10 min (Final Extension)</td> |
| + | <td></td> |
| + | </tr> |
| + | <tr> |
| + | <td>4 °C</td> |
| + | <td></td> |
| + | <td></td> |
| + | </tr> |
| + | </table> |
| + | </ul> |
| | | |
− | <h6>Friday 03/08/2018</h6> | + | <h4 class="text-muted"> Results:</h4> |
− | <h3>Trial 3 (50 nM Cas12a, 62.5 nM crRNA, 200 nM DNaseAlert)</h3>
| + | |
− | <p class="lead">We did this experiment as usual with the following changes: 200 nM DNaseAlert (concentration has been doubled), and again negative control containing the Cas12a enzyme. The experiment was performed using binding buffer (10X, 20mM Tris-HCl,
| + | |
− | pH7.5, 100mM KCL, 5mM MgCl2, 1mMDTT, 5% gylcerol, 50 ug/ml heparin) used in the paper.</p>
| + | |
| | | |
− | <h4>Results:</h4>
| |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/2/24/T--EPFL--FQ-Reporter_Assay_Trial_3.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/f/f4/T--EPFL--PCR_amplification_of_Bcr-Abl_junction-Trial_2.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis</h4> | + | <h4 class="text-muted">Analysis</h4> |
− | <p class="lead">We can see the increase in the level of fluorescence signal (again 1 μM is below 100 nM activator in terms of fluorescence). This time the negative control has the lowest fluorescence. The DNaseAlert concentration was not doubled in the | + | <p class="lead">We could observe a unique band of roughly 100 bp for each tested sample, which would in principle say that the amplification worked well, since we're expecting amplicons of 105 bp (F1 and F4 primers) and 109 bp (F3). However, we got the |
− | positive control by mistake. | + | same band in our negative control sample (water, no DNA template), in which we sould not observe anything, and this suggests a possible DNA contamination of our PCR reaction samples. We could also notice the absence of any band for the |
− | </p> | + | 1 pM/10 fm (without amplification) samples, which is coherent with the fact that we can't detect such low concentrations of DNA without amplification.</p> |
| + | <br> |
| + | <h4 class="text-muted">Discussion</h4> |
| + | <p class="lead">Can we really conclude as to the success of this pcr knowing that our negative control did not work ? Anyway, we're going to do the same PCR again in order to be sure.</p> |
| | | |
− | <h4>Discussion</h4> | + | <h6>Friday, 07/09</h6> |
− | <p class="lead">We might be comparing fluorescence signals which are quite low. Maybe we should once again increase the DNaseAlert concentration.
| + | |
− | </p>
| + | |
| | | |
− | <h6>Saturday 04/08/18</h6> | + | <h3><u>PCR amplification of Bcr-Abl junction-Trial 3.</u></h3> |
− | <h3>Trial 4 (50 nM Cas12a, 62.5 nM crRNA, 200 nM DNaseAlert)</h3>
| + | <p class="lead">Same approach as in the previous trial. This time, we prepared samples containing the Bcr and Abl genes as templates (1 pM), to compare the efficiency of amplification and assess the linear amplification results (see "hypothesis", point |
− | <p class="lead">We followed the protocol with the same modifications as in the 3rd trial (200 nM DNase alert). This time, we also repeated the dilutions in order to obtain activator at concentrations of 1μM, 100nM, 10nM and 1nM (i.e. we tested samples of | + | two). We amplified them using F_primer_chromo_symu_01 (F1) primer and R_primer_chromo_symu_02 (R2). </p> |
− | 100nM, 10nM, 1nM and 0.1nM concentrations). However we forgot to add the buffer after the incubation step.</p> | + | <p class="lead"><i>Read notes of 05/09 for approach and hypothesis for the general "PCR amplification of Bcr-Abl junction" assay.</i></p> |
| | | |
− | <h4>Results</h4> | + | <h4 class="text-muted">Results</h4> |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/1/10/T--EPFL--FQ-Reporter_Assay_Trial4ex-544nm_em-590nm_90min.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/5/55/T--EPFL--PCR_amplification_of_Bcr-Abl_junction-Trial_3.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis</h4> | + | <h4 class="text-muted">Analysis</h4> |
− | <p class="lead">It is clear that we couldn't activate the enzyme this time, since the fluorescence of all our samples is ranging near the negative control’s one at all time. However, we got an increase of fluorescence regarding our positive control compared | + | <p class="lead">Same results as trial 2 unfortunately, we got again this band in our negative control sample. Also, we can observe the exact same band in the samples containing the Abl and Bcr coding sequences, respectively. This suggests that we got an |
− | to other trials (nearly two times more), which is consistent with the fact that we doubled the amount of DNaseAlert substrate, and indicates that we could have forgotten to do so in trial 3.</p> | + | exponential amplification for these rather than linear one. This was not expected, since only one of the primers used is complementary to each sequence (respectively F1 with Bcr and R2 with Abl). Also, the amplification of these two sequences |
| + | should've resulted in amplicons with respectively 239 and 279 bp (c.f. the hypothesis of the experiment, listed on the 05/09), while in this scheme it seems that the same template was amplified...</p> |
| | | |
− | <h4>Discussion</h4> | + | <h4 class="text-muted">Discussion</h4> |
− | <p class="lead">Overall, we can conclude that this trial is a complete failure. This big difference in terms of fluorescent signal with the 3rd trial (same concentration of DNaseAlert substrate) was either due to the fact that we forgot to add the binding | + | <p class="lead">Since it's the second time that we obtain this strange result for the negative control, and the band is the exact replicate of the one obtained in all the other samples, this excludes the hypothesis of a random DNA contamination. We can |
− | buffer in an adequate amount, or maybe because our crRNA has degraded in the meantime</p> | + | state that either we put (again) one of the DNA templates (Bcr-Abl junction most probably) in the control by mistake, or one of the 10 µM primer solution is contaminated with DNA template. As for the Bcr and Abl samples, this same band |
| + | doesn't make sense at all...</p> |
| | | |
− | <hr>
| |
| | | |
− | <h6>Saturday, 11/08/18</h6>
| |
| | | |
− | <h3>Trial 5 (50 nM Cas12a, 62.5 nM crRNA, 160 nM DNaseAlert)</h3>
| |
− | <p class="lead">Another trial following the same protocol using Binding buffer protocol.</p>
| |
| | | |
− | <h4>Results</h4> | + | <h6>Sunday, 09/09/18</h6> |
| + | <p class="lead">Another trial with the same hypothesis as the previous one (amplification done with reverse primer two i.e. R2 for all samples). Still trying to figure out the origin of the band we got in our negative control sample, and to obtain the right |
| + | amplification for each DNA template (i.e. three different amplicons).</p> |
| + | <p class="lead"><i>Read notes of 05/09 for approach and hypothesis for the general "PCR amplification of Bcr-Abl junction" assay.</i></p> |
| + | |
| + | <h4 class="text-muted">Results</h4> |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/d/dc/T--EPFL--FQ-Reporter_Assay_Trial_5.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/b/bc/T--EPFL--PCR_amplification_of_Bcr-Abl_junction-Trial_4.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis/Discussion</h4> | + | <h4 class="text-muted">Analysis</h4> |
− | <p class="lead">The results are not good at all. Again, the negative control sample exhibits an abnormally high fluorescence, 100 nM sample is at the same level of fluorescence than the 1 μM</p> | + | <p class="lead">We still have our strange contamination for the negative control sample. Same pattern of bands.</p> |
| + | <h4 class="text-muted">Discussion</h4> |
| + | <p class="lead">It looks like we're obtaining the same amplicon in each sample, while two of them contain different DNA templates. This could suggest a contamination in one of our 10 µM primer stocks that we've been using so far, perhaps the forward primer |
| + | one (F1), used to amplify different DNA templates, or the reverse primer two (R2), the only reverse primer used so far.</p> |
| | | |
− | <h3>Trial 6 (75 nM LbCas12a, 90 nM crRNA, 160 nM DNaseAlert)</h3> | + | <h6>Monday, 10/09/18</h6> |
− | <p class="lead">Another trial following the same protocol using Binding buffer, where we increased the concentration of LbCas12a to 75 nM and crRNA to 90 nM, compared to the previous trial.</p> | + | <h3><u>Cas12a detection assay-Trial 1</u></h3> |
| + | <p class="lead">We performed our first Cas12a assay for detecting the junction, using the PCR products obtained during "PCR amplification of Bcr-Abl junction-Trial 4", following the hypothesis elaborated on the 05/09.</p> |
| + | <h4 class="text-muted">Results</h4> |
| + | <ul> |
| + | <li>Cas12a assay using different amplicons (as activators) obtained from the amplification of the Bcr-Abl junction with different forward primers (and R2 as reverse primer).</li> |
| + | <figure class="figure"> |
| + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/8/88/T--EPFL--Cas12a_detection_assay-Trial1.png" class="img-fluid rounded" width="800"> |
| + | </figure> |
| + | <li>Cas12a assay performed with F1-R2 amplicons (activators) obtained from both the junction and Bcr-Abl genes.</li> |
| + | <figure class="figure"> |
| + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/d/d9/T--EPFL--Cas12a_detection_assay-Trial1.2.png" class="img-fluid rounded" width="800"> |
| + | </figure> |
| + | </ul> |
| + | |
| + | <h4 class="text-muted">Analysis</h4> |
| + | <p class="lead">Several observations can be made:</p> |
| + | <ul> |
| + | <li>We can clearly see that the primer pair F1-R2 gives the best results (Bcr-Abl junction amplification), followed by F3-R2 and F4-R2. Indeed, the F1-R2 amplicon obtained from the amplification of 1 pM junction part significantly activates |
| + | the Cas12a enzyme and generates a signal ~1.5 times as strong as the one obtained using Bcr or Abl separate genes. Regarding Bcr, this fits more or less with our hypothesis, however Abl gene shouldn't activate the Cas at all.</li> |
| + | <li>Several amplicons of the junction part (F1-R2, F3-R2 both for a concentration of 10 fM and 1 pM before amplification, see first graph) yield almost the same signal than Bcr and Abl normal genes. This was not expected, due to the point |
| + | mutations present in the target strand recognized by the crRNA, and that should have resulted in much less activation of the Cas12a system, with no activation with Abl.</li> |
| + | <li>Activation with F4-R2 amplicon as a target, which shouldn’t be recognized by our crRNA.</li> |
| + | </ul> |
| + | |
| + | <h4 class="text-muted">Discussion</h4> |
| + | <p class="lead">Desired results obtained just with the F1-R2 primers amplification of the junction: ~1.5 folds decrease in signal when using Bcr or Abl as activators in comparison. We have to figure out why our Cas12a enzyme is being activated with F4 amplicons |
| + | and Abl..</p> |
| + | |
| + | <h6>Tuesday, 11/09/18</h6> |
| + | <h3><u>PCR for negative controls without any DNA </u></h3> |
| + | <p class="lead">We wanted to understand why our negative control showed some amplification. The aim is to see whether some of our samples are contaminated. For this, we created six PCR (-) control samples, in which we only added water and different combination |
| + | of primers (see below). Afterwards, we ran a gel with two extra samples: a lane containing Phusion enzyme alone, and one with loading dye, in order to verify that these samples are indeed free of contaminations.</p> |
| + | <p class="lead"><i>Read notes of 05/09 for approach and hypothesis for the general "PCR amplification of Bcr-Abl junction" assay.</i></p> |
| | | |
− | <h4>Results</h4> | + | <h4 class="text-muted">Results</h4> |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/5/57/T--EPFL--FQ-Reporter_Assay_Trial_6.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/5/53/T--EPFL--PCR_amplification_of_Bcr-Abl_junction-Trial_5.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis</h4> | + | <h4 class="text-muted">Analysis</h4> |
− | <p class="lead">First, the signal of 1 μM of activator was below the others, but it increased slightly above the 100 nM, which we were expecting at the end. Also the negative control is increasing which is maybe due to contamination of DNase I enzyme.</p> | + | <p class="lead">It is hard to really know what do the bands actually represent but one of our suspicion is that our reverse primer 2 stock (R_primer_chromo_symu_02) is contaminated by one of our template (probably the Bcr-Abl junction since we got the desired |
| + | band of ~ 105 bp) and that the bands when the reverse primer 1 was used somehow represent the primers (hetero-dimers ?)</p> |
| | | |
| + | <h4 class="text-muted">Discussion</h4> |
| + | <p class="lead">Since we performed the dilutions of our primer stocks again (resuspended at 100 µM) in order to obtain the 10 µM primer solutions that we can use for our PCR, we are convinced that the reverse primer 2 (R2) stock was somehow contaminated |
| + | with Bcr-Abl junction.</p> |
| | | |
− | <h4>Discussion</h4> | + | <h6>Wednesday, 12/09/18</h6> |
− | <p class="lead">This one is has shown the best results so far. At the end of the assay, the fluorescence signal reached the expected pattern.</p> | + | <h3><u>PCR amplification of Bcr-Abl junction-Trial 5</u></h3> |
| + | <p class="lead">Our hypothesis was that our reverse primer 2 stock solution (R_primer_chromo_symu_02-R2) is contaminated. In this trial we tried amplification with our reverse primer 1 (R_primer_chromo_symu_01-R1) to see if it would differ from the amplicon |
| + | produced using the contaminated one (R2). We used 1 pM DNA template for each sample (either Bcr-Abl, Bcr or Abl alone), and two negative controls (no DNA) containing different combinations of primers.</p> |
| + | <p class="lead"><i>Read notes of 05/09 for approach and hypothesis for the general "PCR amplification of Bcr-Abl junction" assay.</i></p> |
| | | |
− | <hr> | + | <h4 class="text-muted">Results</h4> |
| + | <figure class="figure"> |
| + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/7/7f/T--EPFL--PCR_amplification_of_Bcr-Abl_junction-Trial_6.png" class="img-fluid rounded" width="800"> |
| + | </figure> |
| | | |
− | <h6>mONDAY, 13/08/18</h6> | + | <h4 class="text-muted">Analysis </h4> |
| + | <p class="lead">The amplification seem to have worked using R1 (~145 bp). </p> |
| | | |
− | <h3>Trial 7</h3> | + | <h4 class="text-muted">Discussion</h4> |
− | <p class="lead">In this trial, we wanted to evaluate whether the increase in the concentration of Cas12 can give us higher level of signal. We performed this trial with two different concentrations of the enzyme, following the same protocol as usual (with | + | <p class="lead">We can quite confidently say that our R2 reverse primer was contaminated. We'll perform a Cas12a assay with these PCR products.</p> |
− | Binding buffer).</p>
| + | |
| | | |
− | <h4>Results</h4> | + | <h3><u>Cas12a detection assay-Trial 2</u></h3> |
− | <ul>
| + | <p class="lead">We performed another Cas12a assay, using the PCR products obtained from the PCR above ("PCR amplification of Bcr-Abl junction-Trial 5"). </p> |
− | <li>(200 nM LbCas12a, 120 nM crRNA, 160 nM DNaseAlert)</li>
| + | <p class="lead"><i>Read notes of 05/09 for approach and hypothesis for the general "Cas12a detection assays" set of experiments.</i></p> |
− | </ul> | + | <h4 class="text-muted">Reults:</h4> |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/7/77/T--EPFL--FQ-Reporter_Assay_Trial_7.1.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/3/39/T--EPFL--Cas12a_detection_assay-Trial2.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
| + | |
| + | <h4 class="text-muted"> Analysis/Discussion</h4> |
| + | <p class="lead">Obviously this trial did not work. What could have happened:</p> |
| <ul> | | <ul> |
− | <li>(100 nM LbCas12a, 62.5 crRNA, 160 nM DNaseAlert)</li> | + | <li>Problem with Cas12a : crRNA might have been degraded</li> |
| + | <li>Amplification of the wrong template</li> |
| </ul> | | </ul> |
| + | <p class="lead">Since the positive control (DNase I sample) is working fine, we can be confident that the DNaseAlert wasn't degraded.</p> |
| | | |
| + | <h6>Thursday, 13/09/18</h6> |
| + | <h3><u>PCR amplification of Bcr-Abl junction-Trial 6</u></h3> |
| + | <p class="lead">We performed one more time the PCR on our templates (1 pM concentration before amplification), this time using only forward primer 1 (F1) and one of the two reverse primers (R1 or R2). Negative controls included F1 primer and either one |
| + | of the reverse primers, amplified with water as template. As for the gel, we also ran different samples containing F1 forward primer, R1 and R2 reverse primers (diluted at 50 µM, without amplification), as well as two samples containing |
| + | annealed primers F1-R1 and F2-R2 (50 µM, without amplification), in order to figure out whether the bands we were obtaining so far were due to dimers.</p> |
| + | <p class="lead"><i>Read notes of 05/09 for approach and hypothesis for the general "PCR amplification of Bcr-Abl junction" assay.</i></p> |
| + | |
| + | <h4 class="text-muted">Results</h4> |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/e/ec/T--EPFL--FQ-Reporter_Assay_Trial_7.2.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/8/82/T--EPFL--PCR_amplification_of_Bcr-Abl_junction-Trial_7.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis</h4> | + | <h4 class="text-muted">Analysis</h4> |
− | <p class="lead">We can observe an increase in negative controls overall.</p> | + | <ul> |
− | | + | <li>The junction (Bcr-Abl sample) was not amplified by the reverse primer 1, but amplified successfully with the second reverse primer. Is it some manipulation error ?</li> |
− | <h4>Discussion</h4>
| + | <li>Bcr seems to be amplified with both combinations of primers (F1-R1 and F1-R2), However, the size still do not make sense (size between 75 and 200 bp rather than the 239 expected). Abl was not amplified with F1-R1, compared to the discrete |
− | <p class="lead">The problem could be due to contamination of samples with pipettes (because we used the same pipette for taking Dnase I for positive control). We're planning on repeating another trial using new pipettes tips and cleaning well our pipettes.
| + | band obtained when F1-R2 were used. According to our hypothesis (c.f. wednesday 05/09), we shouldn't be able to observe the PCR products of these two samples on a gel due to the lack of sensitivity of the SYBR Safe nucleic acid stain, |
− | Also, one of our TAs highlighted that Cas13a is very unstable at low salt, which means it might bind things that it is not meant to. It could be interesting to investigate the right concentration of buffer to use, since diluting it too
| + | given that the concentration of the amplification products is expected to be really low because of the linear amplification (rather than exponential) that is occuring in these samples (~35 pM since we started from 1 pM of DNA concentration).. |
− | much could lead to a very low sodium concentration which makes the enzyme promiscuous. The promiscuous binding could explain why our negative control actually cleaves.</p> | + | The bands obtained for Abl could be due to contamination (i.e. amplification with Bcr-Abl contaminated primer R2); however, for Bcr F1-R1, it doesn't really make sense. </li> |
− | | + | <li>As for the control sample in which we added water and F1-R2 primers, the amplification resulted in an amplicon of the same size as we would expect if we had amplified the Bcr-Abl junction, thus suggesting that our reverse primer 2 is indeed |
| + | contaminated. Also, adding this primer without amplifying it resulted in a completely different band, suggesting that the amplification is essential in order to obtain a quantity such that we can observe Bcr-Abl fragments on gel.</li> |
| + | </ul> |
| | | |
| + | <h4 class="text-muted">Discussion</h4> |
| + | <p class="lead">the only deduction that can be drawn from this gel is that our concentrated 100 µM stock of the reverse primer 2 (R2) is contaminated. From now on, we decided to work with the first reverse primer (R1).</p> |
| | | |
− | <h3>Trial 8 (200 nM LbCas12a, 120 nM crRNA, 160 nM DNaseAlert)</h3> | + | <h6>Friday, 14/09</h6> |
− | <p class="lead">We're still trying to evaluate whether the increase in the concentration of Cas12a can give us higher level of signal. We performed this trial with two different concentrations of the enzyme. This time we cleaned our pipettes carefully, | + | <h3><u>Cas12a detection assay-Trial 3</u></h3> |
− | used new sterile pipette tips, and made sure for every other aspect so that we wouldn't get any contamination.</p>
| + | <p class="lead">We performed another Cas12a assay, using the PCR products obtained from the PCR above ("PCR amplification of Bcr-Abl junction-Trial 6").</p> |
| + | <p class="lead"><i>Read notes of 05/09 for approach and hypothesis for the general "Cas12a detection assays" set of experiments.</i></p> |
| | | |
− | <h4>Results</h4> | + | <h4 class="text-muted">Results</h4> |
− | <p class="lead">Error bars were drawn just for 1 μM, for more clarity.</p>
| + | |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/b/be/T--EPFL--FQ-Reporter_Assay_Trial_8.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/5/5c/T--EPFL--Cas12a_detection_assay-Trial3.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis/Discussion</h4> | + | <h4 class="text-muted">Analysis</h4> |
− | <p class="lead">This time the rise in sample fluorescence was more satisfying (the 1 uM almost reached the same level of activation as previous positive controls). However, we still have a very sharp rise for the negative control (with Cas12+crRNA), which | + | <ul> |
− | made this trial again unsuccessful. However, the negative control without Cas12 was not activated at all, and even the level of signal decreased somehow.</p> | + | <li>Bcr-Abl F1-R1 amplicon (amplified part of the junction containing the PAM sequence) is up to four times less activating the Cas12a enzyme compared to the other gene templates used (Bcr and Abl amplicons, respectively), which is the contrary |
| + | of what we're expecting to see. Moreover, we do not expect Abl to be an activator for the Cas12a (no PAM sequence).</li> |
| + | <li>Bcr-Abl F1-R2 induces a much higher signal but still way less than Bcr and Abl separate genes.</li> |
| + | <li>Both PCR negative control samples ("Water_F1-R1/F1-R2") are surprinsigly activating the Cas12a enzyme, resulting in a fluorescent signal which is clearly unexpected, since these samples contain no DNA template before their amplification...</li> |
| + | <li>Bcr-Abl without amplification (no PAM sequence) sample (dashed purple line) did not activate the enzyme, which confirms that the absence of the PAM sequence is clearly preventing the Cas12a from cleaving the dsDNA template (Bcr-Abl fragment), |
| + | thus preventing the trans-cleavage of DNaseAlert reporter ssDNA fragments.</li> |
| + | </ul> |
| | | |
| + | <h4 class="text-muted">Discussion</h4> |
| + | <p class="lead">Overall, this trial is a disaster. We did not reach the corresponding levels of activation that we're expecting for the different dsDNA activators (c.f. the hypothesis in "Cas12a detection assays", drawn on the 05/09). More strangely is |
| + | that our dsDNA free samples are somehow activating the Cas12a enzyme. Is our R1 primer also contaminated ? or is it F1 unstead ?? How about Abl being an activator ? Anyway, we're going to perform another assay to figure out.</p> |
| | | |
| + | <h6>Saturday, 15/09/18</h6> |
| + | <h3><u>PCR amplification of Bcr-Abl junction-Trial 7</u></h3> |
| + | <p class="lead">We performed one more time the PCR on our templates (1 pM concentration before amplification), this time using either forward primer 1 (F1) or forward primer 4 (F4), and reverse primer 1 (R1). Negative control included F1 primer and R1 reverse |
| + | primer in combination with water. </p> |
| + | <p class="lead">Here, we also wanted to test the specificity of the PAM-Cas12a interaction. For this, we amplified both our Bcr-Abl junction and Bcr gene with forward primer 4 (F4), with the hypothesis being that the resulting amplified products shouldn't |
| + | be recognized by Cas12a, since the crRNA used is not complementary to the sequence right after the PAM sequence added by this primer. Also for this trial, 30 amplification cycles were ran instead of 35 used until now for the PCR reaction |
| + | with PHUSION polymerase (Thermo Fisher scientific).</p> |
| + | <p class="lead"><i>Read notes of 05/09 for approach and hypothesis for the general "PCR amplification of Bcr-Abl junction" assay.</i></p> |
| | | |
− | <hr> | + | <h4 class="text-muted">Results</h4> |
| + | <figure class="figure"> |
| + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/e/ed/T--EPFL--Cas12a_detection_assay-Trial4.png" class="img-fluid rounded" width="800"> |
| + | </figure> |
| + | <h6>Sunday, 16/09/18</h6> |
| + | <h3><u>Cas12a detection assay-Trial 4</u></h3> |
| + | <p class="lead">We performed another Cas12a assay, using the PCR products obtained from the experiment "PCR amplification of Bcr-Abl junction-Trial 7" done during the previous day. Read notes of 05/09 for approach and hypothesis for the general "Cas12a |
| + | detection assays" set of experiments</p> |
| + | <h4 class="text-muted">Results</h4> |
| + | <figure class="figure"> |
| + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/7/74/T--EPFL--Cas12a_detection_assay-Trial5.png" class="img-fluid rounded" width="800"> |
| + | </figure> |
| + | <h4>Analysis</h4> |
| + | <ul> |
| + | <li>Roughly the same observations as in the previous Cas12a detection assay.</li> |
| + | <li>Activation of Cas12a with the Bcr-Abl F4-R1 amplicon. This is indeed in disagreement with our hypothesis.</li> |
| + | <li>High signal obtained for the PCR negative control sample ("Water_F1-R1", dashed blue line). </li> |
| | | |
− | <h6>Tuesday, 14/08/18</p> | + | </ul> |
| | | |
− | <h3>Trial 9 (200 nM LbCas12a, 120 nM crRNA, 180 nM DNaseAlert)</h3>
| + | <h4 class="text-muted">Discussion</h4> |
− | <p class="lead">We Tried different concentration of salt to see if it influences the way the Cas12a system works. To do this we increased the
| + | <p class="lead">We're starting to think that the dsDNA contamination that we're facing so far may be due to primer F1. The presence of some Bcr-Abl template DNA in this primer would explain why we're getting such an activation with our PCR products containing |
− | binding buffer concentration as well as the NEBuffer 2.1 for another tube. We wanted to see which of the buffer worked better.</p>
| + | Bcr or Abl, as well as the negative control result. We decided to order F1 (F_primer_Chromo_symu_01) as well as R2 (R_primer_Chromo_symu_02) again from Integrated DNA Technologies (IDT).</p> |
| | | |
− | <h4>Results</h4>
| + | <h6>Thursday, 20/09/18</h6> |
− | <ul>
| + | <h3><u>Cas12a detection assay-Trial 5</u></h3> |
− | <li>Activator as template</li>
| + | |
− | </ul>
| + | |
− | <figure class="figure">
| + | |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/6/6c/T--EPFL--FQ-Reporter_Assay_Trial_9.1.png" class="img-fluid rounded" width="800">
| + | |
− | </figure>
| + | |
− | <ul>
| + | |
− | <li>Negative control as template</li>
| + | |
− | </ul>
| + | |
− | <figure class="figure">
| + | |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/6/6e/T--EPFL--FQ-Reporter_Assay_Trial_9.9.png" class="img-fluid rounded" width="800">
| + | |
− | </figure>
| + | |
| | | |
− | <h4>Analysis</h4>
| + | <h4 class="text-muted">Aim:</h4> |
− | <p class="lead">The results are not good at all. Increasing the concentration of one or the other of the two buffers results in an even lower
| + | <p class="lead">For this trial we wanted to check wether the primers somehow activated our cas12a by doing hetero dimers. In this way we could eliminate the possibility of dimers and prioritize the hypothesis of contamination. </p> |
− | activation of the enzyme. Indeed, increasing the concentration of binding buffer reduces both signals in negative control and
| + | <p class="lead">The protocol we followed is : FQ reporter assay V.5 -For primers [20.09.18]</p> |
− | sample with activators. Also Cas12a doesn't get fully activated neither in 1X NEBuffer, nor in 5X, which suggests that using binding
| + | <p class="lead"><i>Read notes of 05/09 for approach and hypothesis for the general "Cas12a detection assays" set of experiments</i></p> |
− | buffer in the future could be more relevant.</p>
| + | <h4 class="text-muted">Results:</h4> |
| + | <h4 class="text-muted">Discussion:</h4> |
| + | <p class="lead">We can see that the annealed primers as well as the individual primers do not activate cas12a. The samples were not amplified which mean that our primers can be contaminated.</p> |
| | | |
| + | <h6>Friday, 21/09/18</h6> |
| + | <h3><u>PCR amplification of Bcr-Abl junction with Plasma - Trial 1</u></h3> |
| + | <h4 class="text-muted">Aim:</h4> |
| + | <p class="lead">To see whether our usual PCR worked correctly when done in plasma. </p> |
| + | <h4 class="text-muted">Results:</h4> |
| + | <figure class="figure"> |
| + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/2/20/T--EPFL--bcr-abl.png" class="img-fluid rounded" width="800"> |
| + | </figure> |
| | | |
− | <h4>Discussion</h4> | + | <h6>Wednesday, 26/09/18</h6> |
− | <p class="lead">We're not sure that using 5x of each buffer is the most efficient way of increasing the salt concentration within the assay, but it | + | <h3><u>PCR amplification of Bcr-Abl junction (20 cycles)-Trial 8</u></h3> |
− | doesn't seem to fix our problem anyways, since increasing the concentration of buffer reduces both signals in negative control and
| + | |
− | sample with activators. However, we got convinced that <STRONG>using binding buffer is a better option</strong>, since it has shown a better
| + | |
− | activation of the Cas12a enzyme. We decided to use it for all the other trials to come.</p>
| + | |
| | | |
− | <hr> | + | <h4 class="text-muted">Aim:</h4> |
| + | <p class="lead">Amplification of the Bcr with the newly received F1 and R2 primers as our old one seemed to have been contaminated.</p> |
| | | |
− | <h6>Wednesday, 15/08/18</h6> | + | <h4 class="text-muted">Results:</h4> |
| + | <figure class="figure"> |
| + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/d/d8/T--EPFL--PCR_amplification_of_Bcr-Abl_junction_Plasma_Trial2.png" class="img-fluid rounded" width="800"> |
| + | </figure> |
| | | |
− | <h3>Trial 10 (200 nM LbCas12a, 120 nM crRNA, 180 nM DNaseAlert)</h3> | + | <h4 class="text-muted">Discussion:</h4> |
− | <p class="lead">Compared with the previous trial, we have once again diluted our activators. In addition, we have transcribed and purified our crRNA again and this time we made sure that we did every step in the right way. We wanted to try different kinds | + | <p class="lead">Seems to work! Only the Bcr-Abl has been amplified as should be. But contamination (on the comb? in the ladder?)</p> |
− | of negative in order to check whether we had contamination in our of our tubes which could explain our high negative control.</p>
| + | |
| | | |
− | <h4>Results</h4> | + | <h6>Thursday, 27/09/18</h6> |
| + | <h4 class="text-muted">Aim: </h4> |
| + | <p class="lead">To try the gel again with the previous pcr products (20 cycles) as the last gel was contaminated</p> |
| + | <h4 class="text-muted">Results:</h4> |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://2018.igem.org/File:T--EPFL--FQ-Reporter_Assay_Trial_10.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/4/4f/T--EPFL--PCR_amplification_of_Bcr-Abl_junction_Plasma_Trial3.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| + | <h4 class="text-muted">Discussion:</h4> |
| + | <p class="lead">The amplification seems to have been successful! Only the bcr-abl sequence seem to have been amplify. The bands are quite faint so we will reproduce the same PCR with more cycles.</p> |
| | | |
− | <h4>Analysis</h4>
| |
− | <p class="lead">The negative control sample which contains crRNA without Cas12a, does not produce a signal, which suggests that our purified crRNA is free of DNases.</p>
| |
| | | |
− | <h4>Discussion</h4> | + | <h3><u>Cas12a detection assay-Trial 5 (from PCR products trial 9)</u></h3> |
− | <p class="lead">There is no Dnase contamination in our crRNA solution, nor in our Cas12 solution or in our DnaseAlert substrate. The activation of cas12a in our sample seems to be due to something other than contamination...</p>
| + | |
| | | |
− | <hr>
| |
− | <h6>Friday, 17/08/18 </h6>
| |
− | <h3>Trial 11</h3>
| |
− | <p class="lead">In this experiment with tried different concentration of crRNA while keeping Cas12a concentration constant (50nM cas12a vs. 62.5nM/50nM/36.25nM/25nM of crRNA). We did the pre-incubation at 37°C for around 15minutes.</p>
| |
− |
| |
− | <h4>Results</h4>
| |
− | <ul>
| |
− | <li>(50 nM LbCas12a, 36.25 nM crRNA, 200 nM DNaseAlert)</li>
| |
− | </ul>
| |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/6/69/T--EPFL--FQ-Reporter_Assay_Trial_11.1.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/8/8b/T--EPFL--Cas12a_detection_assay-Trial6.png" class="img-fluid rounded" width="800"> |
− | </figure>
| + | |
− | <ul>
| + | |
− | <li>(50 nM LbCas12a, 50 nM crRNA, 200 nM DNaseAlert)</li>
| + | |
− | </ul>
| + | |
− | <figure class="figure">
| + | |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/b/b8/T--EPFL--FQ-Reporter_Assay_Trial_11.2.png" class="img-fluid rounded" width="800">
| + | |
− | </figure>
| + | |
− | <ul>
| + | |
− | <li>(50 nM LbCas12a, 62.5 nM crRNA, 200 nM DNaseAlert)</li>
| + | |
− | </ul>
| + | |
− | <figure class="figure">
| + | |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/6/6e/T--EPFL--FQ-Reporter_Assay_Trial_11.3.png" class="img-fluid rounded" width="800">
| + | |
| </figure> | | </figure> |
| | | |
− | <ul> | + | <h4 class="text-muted">Discussion</h4> |
− | <li>(50 nM LbCas12a, 25 nM crRNA, 160 nM DNaseAlert)</li>
| + | <p class="lead">The results are not as expected: the negative control N of the cas12a assay (Cas12a with crRNA and DNaseAlert) is highly fluorescent. The sample in which we would like to detect the highest level of fluorescence, Bcr-Abl with F1-R2, is quite |
− | </ul> | + | low compared to samples which should barely activate the enzyme (Bcr F1-R2). </p> |
| + | |
| + | <h6>Friday, 28/09/18</h6> |
| + | <h3><u>PCR amplification of Bcr-Abl junction (30 cycles)-Trial 10</u></h3> |
| + | |
| + | <h4 class="text-muted">Results:</h4> |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/b/bd/T--EPFL--FQ-Reporter_Assay_Trial_11.4.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/d/d6/T--EPFL--trial10.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis</h4> | + | <h4 class="text-muted">Discussion:</h4> |
− | <p class="lead">Once again the negative controls do not work and the fluorescent signal produced was above all the others which still makes no sense since the enzyme should not be active in that sample (no target in the solution).</p> | + | <p class="lead">As we can see the results differ a lot from the previous gel (20 cycles). There seem to be some contamination althought the R1 and F1 primers are new. To make sure it is contamination that happened between this gel and the last we will reproduce |
| + | those same pcr.</p> |
| | | |
− | <h4>Discussion</h4> | + | <h6>Saturday, 29/09/18</h6> |
− | <p class="lead">We were thinking of doing the experiments as in the NEB protocol given with the cas12a (with NEBuffer + 10min preincubation at room temperature and a ratio of 10:10:1 of cas12a/crRNA/activator). Also thinking of ordering the Ascas12a from | + | <h3><u>PCR amplification of Bcr-Abl junction (20 cycles)-Trial 11</u></h3> |
− | IDT.
| + | |
− | </p>
| + | |
| | | |
− | <hr> | + | <h4 class="text-muted">Aim:</h4> |
| + | <p class="lead">To remake the same pcr as previous to check for contamination</p> |
| + | <h4 class="text-muted">Results:</h4> |
| | | |
− | <h6>Sunday, 19/08/18</h6> | + | <figure class="figure"> |
| + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/f/f9/T--EPFL--trial11.png" class="img-fluid rounded" width="800"> |
| + | </figure> |
| | | |
− | <h3>Trial 12</h3> | + | <h4 class="text-muted">Discussion:</h4> |
− | <p class="lead">We repeated once again the assay, this time according to the <a href="https://international.neb.com/protocols/2017/12/19/in-vitro-digestion-of-dna-with-engen-lba-cas12a-cpf1-neb-m0653">Neb protocol</a> given with LbCas12a</p> | + | <p class="lead">The gel is the same as the first 20 cycles gel. This suggest that there was no contamination in the F1, R2 primers or nuclease free water between the previous 20 cycles gel and the 30 cycles gel. We want to see the 30 cycles amplification |
| + | again. |
| + | </p> |
| | | |
− | <ul> | + | <h3><u>Cas12a detection assay-Trial 6 (from PCR products trial 11)</u></h3> |
− | <li>10 minute preincubation at 25°C</li>
| + | |
− | <li>same concentration of crRNA as cas12a</li>
| + | |
− | </ul>
| + | |
| | | |
− | <table>
| |
− | <tr>
| |
− | <th></th>
| |
− | <th>A</th>
| |
− | <th>B</th>
| |
− | <th>N</th>
| |
− | <th>P</th>
| |
− | </tr>
| |
− | <tr>
| |
− | <td>NEBuffer</td>
| |
− | <td>5</td>
| |
− | <td>5</td>
| |
− | <td>5</td>
| |
− | <td>5</td>
| |
− | </tr>
| |
− | <tr>
| |
− | <td>Cas12a (1um)</td>
| |
− | <td>1.5</td>
| |
− | <td>1.5</td>
| |
− | <td>1.5</td>
| |
− | <td>-</td>
| |
− | </tr>
| |
− | <tr>
| |
− | <td>crRNA(1um)</td>
| |
− | <td>1.5</td>
| |
− | <td>1.5</td>
| |
− | <td>1.5</td>
| |
− | <td>-</td>
| |
− | </tr>
| |
− | <tr>
| |
− | <td>activator</td>
| |
− | <td>5 [tube 2: 1uM]</td>
| |
− | <td>5 [tube 3: 0.1uM]</td>
| |
− | <td>-</td>
| |
− | <td>-</td>
| |
− | </tr>
| |
− | <tr>
| |
− | <td>DNaseAlert</td>
| |
− | <td>5</td>
| |
− | <td>5</td>
| |
− | <td>5</td>
| |
− | <td>5</td>
| |
− | </tr>
| |
− | <tr>
| |
− | <td>DNase I</td>
| |
− | <td>-</td>
| |
− | <td>-</td>
| |
− | <td>-</td>
| |
− | <td>-</td>
| |
− | </tr>
| |
− | <tr>
| |
− | <td>NFW</td>
| |
− | <td>32</td>
| |
− | <td>32</td>
| |
− | <td>37</td>
| |
− | <td>39.8</td>
| |
− | </tr>
| |
− | <tr>
| |
− | <td>Total</td>
| |
− | <td>50</td>
| |
− | <td>50</td>
| |
− | <td>50</td>
| |
− | <td>50</td>
| |
− | </tr>
| |
− | </table>
| |
− |
| |
− | <h4>Results</h4>
| |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/b/b1/T--EPFL--FQ-Reporter_Assay_Trial_12.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/e/e5/T--EPFL--cas12a_trial6.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis</h4> | + | <h4 class="text-muted">Discussion:</h4> |
− | <p class="lead">This method does not seem to resolve our negative control problem in which there is still a mysterious activation of the enzyme that is once again cleaving the ssDNA reporters without activation.</p> | + | <p class="lead">The negative control is not as high as it previously was but still too high. We think there might be some problem with the new Cas12a protein we received. The Bcr-Abl F1-R2 is the sample which activates cas the most which is what we want! |
| + | But the Abl F1-R2 sample shows the highest fluorescence which is not a good thing since abl sequence is not only not complementary to the crRNA but also doesn't contain the PAM sequence. </p> |
| | | |
− | <h4>Discussion</h4>
| |
− | <p class="lead">We're going to stick to the other protocols based on our reference paper for the next trials...</p>
| |
| | | |
− | <h6>Monday, 20/08/18</h6> | + | <h6>Sunday, 30/09/18</h6> |
− | <h3>Trial 13</h3>
| + | |
− | <p class="lead">We're trying to test some combinations of different concentrations of LbCas12a and crRNA (while keeping the concentration of activator constant : 100 nM), to see which ones work the best for our system. Also testing whether not incubating
| + | |
− | the samples could lead to better results. This time, we didn’t first create a Master Mix with 4X concentration of Cas12+crRNA (200 nM of Cas12 + 250 nM of crRNA) as in the paper, where we needed to dilute them to 1X (50 nM of Cas12 + 62.5
| + | |
− | nM of crRNA). Instead, we directly put the right amount in order to obtain the final concentration of Cas12+crRNA in each sample separately, and performed the assay with or w/o pre-incubation of the Cas12a/crRNA complex (for assembling).</p>
| + | |
| | | |
− | <h4>Results</h4> | + | <h3><u>PCR amplification of Bcr-Abl junction (30 cycles)-Trial 12</u></h3> |
− | <ul>
| + | |
− | <li>FQ1 (50 nM LbCas12a, 62.5 nM crRNA, 160 nM DNaseAlert), with Pre-incubation</li>
| + | |
− | </ul>
| + | |
| | | |
| + | <h4 class="text-muted">Aim:</h4> |
| + | <p class="lead">To remake the 30 cycles pcr in order to see how sensitive and specific our amplifcation is. </p> |
| + | |
| + | <h4 class="text-muted">Results:</h4> |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/8/89/T--EPFL--FQ-Reporter_Assay_Trial_13.1.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/b/ba/T--EPFL--Trial12.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <ul> | + | <h4 class="text-muted">Discussion:</h4> |
− | <li> FQ2 (75 nM LbCas12a, 62.5 nM crRNA, 160 nM DNaseAlert), with pre-incubation.</li>
| + | <p class="lead">Again there are some bands in the negative controls as well as in the bcr and abl lanes. Next time we will either put a lower concentration to start with or/and put background DNA (from salmon sperm DNA). Hopefully the negative controls |
− | </ul>
| + | will be empty again.</p> |
| | | |
| + | <h3><u>Cas12a detection assay-Trial 7 (from PCR products trial 12)</u></h3> |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/4/43/T--EPFL--FQ-Reporter_Assay_Trial_13.2.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/c/c6/T--EPFL--Cas12a_trial12.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
− | <ul>
| |
− | <li>FQ3 (75 nM LbCas12a, 90 nM crRNA, 160 nM DNaseAlert), with pre-incubation.</li>
| |
− | </ul>
| |
| | | |
| + | <h4 class="text-muted">Discussion:</h4> |
| + | <p class="lead">The negative control is once again way too high. We will try to do it in plasma next time as we think that maybe having background DNA will make the amplification more specific. </p> |
| + | |
| + | <hr> |
| + | |
| + | <h6>Monday, 01/10/18</h6> |
| + | <h3><u>PCR amplification of Bcr-Abl junction with Plasma - Trial 13</u></h3> |
| + | <p class="lead">We wanted to try amplificaiton in Plasma again as we believe that having some sorts of DNA background could help our amplification specificity. We chose to make a 30 cycles reactions to have clear bands. </p> |
| + | |
| + | <h4 class="text-muted">Results:</h4> |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://2018.igem.org/File:T--EPFL--FQ-Reporter_Assay_Trial_13.3.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/e/e4/T--EPFL--trial13_30cycles.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <ul> | + | <h3><u>Cas12a detection assay in plasma-Trial 1 (from plasma PCR products trial 13)</u></h3> |
− | <li>FQ4 (75 nM LbCas12a, 90 nM crRNA, 160 nM DNaseAlert), without pre-incubation.</li>
| + | |
− | </ul>
| + | |
| | | |
| + | <h4 class="text-muted">Results:</h4> |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/d/d5/T--EPFL--FQ-Reporter_Assay_Trial_13.4.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/8/8c/T--EPFL--cas12a_plasma.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis</h4> | + | <h4 class="text-muted">Analysis:</h4> |
− | <p class="lead">We were able to get good activation for each of our samples (FQ1, FQ2, FQ3 and FQ4) with a relatively low rate of activation in the negative control for each except for the second one. Surprisingly, the experiment without pre-incubation | + | <p class="lead">The activation is overall very small. In this assay we used the remaining of an older cas12a protein. Maybe the concentration of the protein wasn't high enough. Another possibility is that the amplification was not successful.</p> |
− | gave up the best yield in terms of fluorescence.</p>
| + | |
− | <p class="lead">Apart from that, we can also see through the error bars that we have a lot of variations between our two measured duplicates (not drawn for negative and positive controls), and from this, the only sample to consider for success would be
| + | |
− | the FQ4 one (without pre-incubation).</p>
| + | |
| | | |
− | <h4>Discussion</h4> | + | <h6>Wednesday, 03/10/18</h6> |
− | <p class="lead">We finally concluded that the problem was related to the Master mix step: the cas12a and crRNA are incubated at too high of a concentration. Also, in the samples without pre-incubation we were able to get a very good result which could mean | + | <h3><u>PCR amplification of Bcr-Abl junction with Plasma (30 cycles)- Trial 14</u></h3> |
− | that pre-incubation made Cas12a not as activated as it should be.</p>
| + | |
| | | |
− | <p class="lead">Besides, we're getting too much variation for each sample. Should we use more replica for each sample (right now we are using two replicas) ? or is it from the device ? Another possible sources of errors would be either pipetting or bubbles | + | <p class="lead">As last cas12a assay revealed no activation we decided to try again with the same samples. We removed the primer F4 as we don't find it necessary.</p> |
− | formation... | + | <figure class="figure"> |
− | </p> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/6/64/T--EPFL--PCR_abl_trial14.png" class="img-fluid rounded" width="800"> |
| + | </figure> |
| | | |
− | <h6>Tuesday, 21/08/18</h6>
| + | <p class="lead">The bands look very faint for a 30cycles amplification. </p> |
− | <h4>Trial 14</h4>
| + | |
− | <p class="lead">Following the same hypothesis of the 13th trial, we're still looking for the ideal concentrations of LbCas12a and crRNA to use in our assay. Four Samples (100 nM of dsDNA activator) where either left to pre-incubate or not, and contained | + | |
− | different amounts of the enzyme and crRNA. No master mix was prepared. We also did the pipetting more carefully and tried our best to avoid bubbles.</p>
| + | |
| | | |
− | <h4>Results</h4> | + | <h3><u>Cas12a detection assay in plasma-Trial 2 (from plasma PCR products trial 14)</u></h3> |
− | <ul>
| + | |
− | <li>FQ1 (50 nM LbCas12a, 62.5 nM crRNA, 160 nM DNaseAlert), with pre-incubation</li>
| + | |
− | </ul>
| + | |
| | | |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/2/21/T--EPFL--FQ-Reporter_Assay_Trial_14.1.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/1/19/T--EPFL--cas12a_plasma-trial2.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <ul> | + | <p class="lead">Hooray! This assay is sucessful!! Bcr-Abl is activated as it should be. The other samples show small to no activation at all. </p> |
− | <li>FQ2 (75 nM LbCas12a, 62.5 nM crRNA, 160 nM DNaseAlert), with pre-incubation</li>
| + | |
− | </ul> | + | <h6>Thursday, 04/10/18</h6> |
| + | <h3><u>PCR amplification of Bcr-Abl junction with Plasma - Trial 15</u></h3> |
| + | <p class="lead">Here we wanted to try different kind of Bcr-Abl concentration to see how the cas12a activation would change. </p> |
| | | |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/1/19/T--EPFL--FQ-Reporter_Assay_Trial_14.2.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/1/10/T--EPFL--PCR_abl_trial15.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <ul> | + | <h3><u>Cas12a detection assay in plasma-Trial 3 (from plasma PCR products trial 15)</u></h3> |
− | <li>FQ3 (75 nM LbCas12a, 90 nM crRNA, 160 nM DNaseAlert), with pre-incubation</li>
| + | |
− | </ul>
| + | |
| | | |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/2/25/T--EPFL--FQ-Reporter_Assay_Trial_14.3.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/3/31/T--EPFL--cas12a_plasma_trial3.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <ul> | + | |
− | <li>FQ4 (75 nM LbCas12a, 90 nM crRNA, 160 nM DNaseAlert), without pre-incubation</li>
| + | <h6>Friday, 05/10/18</h6> |
− | </ul> | + | <h3><u>PCR amplification of Bcr-Abl junction with Plasma - Trial 16 (25 cycles)</u></h3> |
| + | <p class="lead">We decided to change our approach and to look at the difference in activation of a sample with healthy cfDNA (the background: Bcr and Abl) compared to a sample which contains both the background and the mutated cfDNA (Bcr-Abl). This is indeed |
| + | closer to the reality as a patient with cancer will have both ctDNA and cfDNA corresponding to the healthy cells.</p> |
| | | |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/3/31/T--EPFL--FQ-Reporter_Assay_Trial_14.4.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/e/e4/T--EPFL--Clipboard.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis</h4>
| + | <p class="lead">There is very faint bands on the gel which is maybe due to the fact that we only did around 25 cycles. </p> |
− | <p class="lead">We can see the effect of pre-incubation here: without pre-incubation the slope is lower than with pre-incubation for the same concentrations of both Cas12a and crRNA (FQ3 vs FQ4). Also, we can see that the 75 nM of Cas12a and 90 nM of crRNA | + | |
− | are the most efficient concentrations here (regardless of the incubation) since these samples (FQ3 and FQ4) gave out the highest signal.</p>
| + | |
| | | |
| + | <h3><u>Cas12a detection assay in plasma-Trial 4 (from plasma PCR products trial 16)</u></h3> |
| | | |
− | <h4>Discussion</h4> | + | <figure class="figure"> |
− | <p class="lead">It looks like we're going in the right direction for figuring out the optimal concentrations to use in our assay.</p>
| + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/3/3c/T--EPFL--Cas12a_plasma_trial4.png" class="img-fluid rounded" width="800"> |
| + | </figure> |
| | | |
| + | <p class="lead">Sadly the results are not as expected.. The background which contains no Bcr-Abl activated the Cas12a targeting Bcr-Abl more than the sample that actually has template. </p> |
| | | |
− | <h6>Friday, 24/08/18</h6> | + | <h6>Tuesday, 09/10/18</h6> |
− | <h3>Trial 16</h3> | + | <h3><u>PCR amplification of Bcr-Abl junction with Plasma - Trial 17 (30 cycles)</u></h3> |
− | <p class="lead">We did this experiment with the same hypothesis as in the previous two trials. We ran different assays with different concentrations of Cas12a and crRNA. All samples were incubated (for Cas12a assembling).</p> | + | <p class="lead">Today we wanted to reproduce the same kind of experience as yesterday but with two different concentrations as we've previously seen that template concentrations can sometimes affect cas12a.</p> |
− | | + | |
− | <ul>
| + | |
− | <li>FQ6 (62.5 nM LbCas12a, 75 nM crRNA, 160 nM DNaseAlert), with pre-incubation</li>
| + | |
− | </ul>
| + | |
| | | |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/f/ff/T--EPFL--FQ-Reporter_Assay_Trial_16.1.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/e/ef/T--EPFL--yetanothergel.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
− | <ul> | + | |
− | <li>FQ2 (75 nM LbCas12a, 62.5 nM crRNA, 160 nM DNaseAlert), with pre-incubation</li>
| + | <h3><u>Cas12a detection assay in plasma-Trial 5 (from plasma PCR products trial 17)</u></h3> |
− | </ul>
| + | |
| | | |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/e/e6/T--EPFL--FQ-Reporter_Assay_Trial_16.2.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/1/12/T--EPFL--yag2.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
| <ul> | | <ul> |
− | <li>FQ3 (75 nM LbCas12a, 90 nM crRNA, 160 nM DNaseAlert), with pre-incubation</li> | + | <h5>Samples 1 :</h5> |
| + | <li>b1 1pM</li> |
| + | <li>BAb 10fM</li> |
| + | <h5>Samples 2:</h5> |
| + | <li>b2 100fM</li> |
| + | <li>BAb2 1fM</li> |
| </ul> | | </ul> |
| + | |
| + | <p class="lead">Again, a very high negative control from plasma. It is not surprising as there was a band in the gel above for the negative control. Except this we can see that the samples containing the targeted Bcr-Abl junction is in both case more activated |
| + | than the ones without (the background). This is a good thing. Next time we'll try the same again with possibly different concentrations and hopefully we'll get a sucessful negative control.</p> |
| + | |
| + | <h6>Wednesday 10/10/18</h6> |
| + | <h3><u>PCR amplification of Bcr-Abl junction with Plasma - Trial 18 (30 cycles)</u></h3> |
| + | <p class="lead">We tried to do the amplification one last time under the same conditions as last time. In addition we tried another concentration.</p> |
| | | |
| <figure class="figure"> | | <figure class="figure"> |
− | <img alt="Image" src="https://static.igem.org/mediawiki/2018/e/e7/T--EPFL--FQ-Reporter_Assay_Trial_16.3.png" class="img-fluid rounded" width="800"> | + | <img alt="Image" src="https://static.igem.org/mediawiki/2018/a/ac/T--EPFL--yag3.png" class="img-fluid rounded" width="800"> |
| </figure> | | </figure> |
| | | |
− | <h4>Analysis</h4>
| + | <p class="lead">We can see that the samples containing the Bcr-Abl segment are brighter and larger than the one without. The problem is that even the negative control has a band: the same band which are present in every background only sample.</p> |
− | <p class="lead">Overall, this Trial was a success, and by looking at the slopes, we can say that the optimal concentrations of Cas12a and crRNA for our system were obtained for FQ6 sample (62.5 nM LbCas12a and 75 nM crRNA), since we got the sharpest slope, | + | |
− | i.e. faster activation of Cas, for our sample of interest, which surpassed the positive control.</p>
| + | |
| | | |
− | <h4>Discussion</h4> | + | <h3><u>Cas12a detection assay in plasma-Trial 6(from plasma PCR products trial 18)</u></h3> |
− | <p class="lead">We finished our optimization of the concentrations after obtaining a very nice result with our FQ6 sample, and an activation which reaches its maximum after approximatively 80 minutes. For the next assays, we're planning on working with
| + | |
− | 62.5 nM of LbCas12a and 75 nM crRNA while maybe trying to change the concentration of dsDNA activator to see how it affects the signal.</p>
| + | |
| | | |
| | | |